GlassScriptPhysician profile
Sara R Busch
NPI 1669007100
$3,918.12
in general payments reported to CMS, 2019-2025
36 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $864 · 2023: $629 · 2024: $1,936 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,902 · Education: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,901.53 |
| Education | $153.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $731.58 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $479.25 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $374.87 | 2023-2025 | Stelara, Tremfya |
| Lilly USA, LLC | $308.60 | 2021-2025 | Omvoh, Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $277.83 | 2021-2025 | Entyvio |
| Aimmune Therapeutics, INC. | $170.84 | 2024-2025 | Zenpep |
| Qol Medical, LLC | $169.50 | 2023-2024 | Sucraid, Sucraid |
| Ardelyx, INC. | $166.32 | 2023-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $137.74 | 2023-2024 | Ocaliva |
| Astellas Pharma US INC | $128.20 | 2021 | |
| Genzyme Corporation | $108.50 | 2023-2024 | |
| Celgene Corporation | $90.20 | 2023-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $77.82 | 2024-2025 | Dupixent |
| Biogen, INC. | $63.88 | 2021 | |
| Ironwood Pharmaceuticals, INC | $61.48 | 2024-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $60.42 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $46.96 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $46.04 | 2021 | |
| Amarin Pharma, INC. | $39.32 | 2021 | |
| Mirum Pharmaceuticals, INC. | $34.97 | 2025 | Cholbam, Chenodal, Livmarli |
| Ucb, INC. | $34.52 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $31.73 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $30.70 | 2021 | |
| Eisai INC. | $28.21 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $26.16 | 2021 | |
| Janssen Pharmaceuticals, INC | $25.85 | 2021 | |
| Boston Scientific Corporation | $23.72 | 2025 | Intracept |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.63 | 2024 | Cyltezo |
| Merck Sharp & Dohme LLC | $18.11 | 2021 | |
| Mallinckrodt Hospital Products INC. | $17.15 | 2024 | Terlivaz |
| Braintree Laboratories, INC. | $16.37 | 2025 | Suflave |
| Bayer Healthcare Pharmaceuticals INC. | $15.35 | 2021 | |
| Ge Healthcare | $15.35 | 2021 | |
| Celltrion USA INC. | $14.44 | 2025 | Vegzelma |
| Amgen INC. | $13.14 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Busch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.